Bladder Cancer
TOTEM is a non-commercial trial to evaluate the addition of temsirolimus to the standard 2-drug cisplatin / gemcitabine chemotherapy for first line treatment of patients with advanced bladder cancer.
BOLERO is a non-commercial trial to test the feasibility of randomising patients with muscle-invasive bladder cancer between open or minimal access surgery.
SUCCINCT is a non-commercial trial to evaluate the addition of sunitinib to standard 2-drug cisplatin / gemcitabine chemotherapy for first line treatment of patients with advanced bladder cancer
TOUCAN is a phase II, parallel group, double –blind randomised controlled trial. The trial will evaluate whether the addition of a new oral drug vandetanib, which slows down cancer growth and the growth of tumour blood vessels, to carboplatin and gemcitabine chemotherapy makes this regimen more efficient as a 1st line treatment in patients with advanced urothelial cancers for whom it has been decided that this is a suitable form of treatment.
Breast Cancer
ZICE is a randomised, phase III multi-centre open-label trial to evaluate two types of bisphosphonate therapy in breast cancer patients with bone metastases. The study will compare the rate of skeletally related events in participants treated with zoledronate infusions 3-4 weekly versus ibandronate tablets daily. Eligible patients will be randomly allocated to either treatment on a 1:1 basis.
QUALZICE is a QUALitative exploration of the experiences of the patients from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates at clinic or home.
EXEMESTANE is a randomised double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant Tamoxifen for 2-3 years, comparing subsequent adjuvant Exemestane treatment with further Tamoxifen.
Lung Cancer
FRAGMATIC is a non-commercial trial to evaluate the addition of sunitinib to standard 2-drug cisplatin / gemcitabine chemotherapy for first line treatment of patients with advanced bladder cancer
Go to the FRAGMATIC Trial Page
BRITECOG is an assessment of respondent comprehension of and ability to provide valid response to four outcome measure for assessing breathlessness.
NMES - Is neuromuscular electrical stimulation an acceptable and feasible supportive therapy for patients with non-small cell lung cancer receiving palliative chemotherapy?
Metastatic Colorectal Cancer
FOCUS 3 is a study to determine the feasibility of molecular selection of therapy using K-ras and topo-1 in patients with metastatic or locally advanced colorectal cancer. (Qualitative and patient experience components only)
FOLFERA is a phase II, parallel group double-blind randomised controlled trial in patients with advanced urothelial cancer for whom it has been decided that FOLFIRI chemotherapy is a suitable form of treatment.
The study will determine if the addition of a new oral drug, (ZD4054) that blocks key messages that cancer cells need to survive and grow, to FOLFIRI chemotherapy makes this regimen more effective at killing colorectal cancer cells such that disease progression is delayed.
Oesophageal Cancer
SCOPE 1 is a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without Cetuximab, in carcinoma of the oesophagus.
Pancreatic Cancer
SCALOP is a multi-centre randomised phase II study of induction chemotherapy followed by gemcitabine or capecitabine based chemoradiotherapy for locally advanced non-metastatic pancreatic cancer.
Vulval Intraepithelial Neoplasia
RT3VIN is a randomised phase II multi-centre clinical trial of topical treatment in women with vulval intraepithelial neoplasia.